Sector News

Sanofi signs up Evotec in 250M euro preclinical pact

December 3, 2014
Life sciences
Sanofi is deep in talks with Evotec about a five-year “multi-component strategic alliance” that would be worth at least 250 million euros to the German biotech.
 
The firms are holding “exclusive negotiations” about three initiatives, the most striking of which will see Evotec acquire Sanofi’s troubled operations in Toulouse “to build a European centre of excellence for compound management and drug discovery services”.
 
The French drugmaker had planned to run down operations at Toulouse but under pressure from the government and trades unions, in May 2013, it pledged to keep doing research at the site for five more years. Now some 200 of its scientists working in Toulouse will transfer to Evotec.
 
The proposed deal will also see Evotec license from Sanofi a portfolio including “five well-advanced pre-clinical projects in oncology” that will be progressed to the investigational new drug stage jointly before potential partnering. It also includes a “French academic bridge programme”.
 
The third element will see the companies combine their libraries to make them available for screening to Evotec’s partners. Sanofi’s library in Toulouse site has over one million compounds and this, added to Evotec’s 400,000 or so compounds, will create “a very large and valuable source of starting points for drug discovery”.
 
The 250 million euro figure includes a “sizeable upfront cash payment”, plus royalties. Werner Lanthaler, Evotec chief executive, said the collaboration “is a major milestone in the drug discovery space”. It also “accelerates Evotec’s strategy to become the leading drug discovery partner to the pharma and biotech industry as well as academia”.
 
Elias Zerhouni, head of R&D for the Paris-based giant, said  “open innovation is a key driver of Sanofi’s strategy” and Evotec is “a company that fits our quality expectations and our strategic vision”. He added that the collaboration “will secure the future for our employees in Toulouse and importantly accelerate our pipeline productivity”.
 
By Kevin Grogan
 
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend